HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice
- Author:
Taewoo KIM
1
;
Seohoe SONG
;
Yeongwon PARK
;
Sinil KANG
;
Hyemyung SEO
Author Information
- Publication Type:Original Article
- Keywords: Parkinson’s disease (PD); Histone deacetylase (HDAC); Valproic acid (VPA); Neuroprotection
- MeSH: Acetylation; Animals; Cell Survival; Dopaminergic Neurons; Epigenomics; Gene Expression; Histone Deacetylases; Histones; Lewy Bodies; Mice; Mice, Transgenic; Microglia; Models, Genetic; Movement Disorders; Neurodegenerative Diseases; Neurons; Neuroprotection; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase; Valproic Acid
- From:Experimental Neurobiology 2019;28(4):504-515
- CountryRepublic of Korea
- Language:English
- Abstract: Parkinson’s disease (PD) is one of the late-onset neurodegenerative movement disorder. Major pathological markers of PD include progressive loss of dopaminergic neurons, Lewy body formation, genetic mutations, and environmental factors. Epigenetic regulation of specific gene expression via impaired histone acetylation is associated with neuronal dysfunction in various neurodegenerative diseases. In this study, we hypothesized that histone deacetylase (HDAC) inhibitor, valproic acid (VPA), can improve motor function by enhancing cell survival in PD genetic model mice with LRRK2 R1441G mutation. To address this question, we administered VPA in LRRK2 R1441G transgenic mice to determine whether VPA affects 1) histone acetylation and HDAC expression, 2) dopaminergic neuron survival, 3) inflammatory responses, 4) motor or non-motor symptoms. As results, VPA administration increased histone acetylation level and the number of tyrosine hydroxylase (TH) positive neurons in substantia nigra of LRRK2 R1441G mice. VPA reduced iba-1 positive activated microglia and the mRNA levels of pro-inflammatory marker genes in LRRK2 R1441G mice. In addition, VPA induced the improvement of PD-like motor and non-motor behavior in LRRK2 R1441G mice. These data suggest that the inhibition of HDAC can be further studied as potential future therapeutics for PD.
